{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:45:19Z","timestamp":1793432719034,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,28]]},"DOI":"10.7759\/cureus.63420","type":"journal-article","created":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:09:50Z","timestamp":1719619790000},"source":"Crossref","is-referenced-by-count":10,"title":["Understanding the Spectrum and Management of Post-Tuberculosis Lung Disease: A Comprehensive Review"],"prefix":"10.7759","author":[{"given":"Sankalp","family":"Yadav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Rawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Tuberculosis","author":"Bloom BR","year":"2017","unstructured":"Bloom BR, Atun R, Cohen T, et al.. Tuberculosis. Major Infectious Diseases, 3rd edition. Holmes KK, Bertozzi S, Bloom BR, et al. (ed): The International Bank for Reconstruction and Development\/The World Bank, Washington (DC); 2017."},{"key":"ref2","unstructured":"WHO. Tuberculosis. (2024). Accessed: May 16, 2024: https:\/\/www.who.int\/health-topics\/tuberculosis."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.60280","article-title":"Advancements in artificial intelligence for the diagnosis of multidrug resistance and extensively drug-resistant tuberculosis: a comprehensive review","volume":"16","author":"Shanmuga KP","year":"2024","unstructured":"Shanmuga KP, Parivakkam Mani A, Geethalakshmi S, Yadav S. Advancements in artificial intelligence for the diagnosis of multidrug resistance and extensively drug-resistant tuberculosis: a comprehensive review. Cureus. 2024, 16:e60280. 10.7759\/cureus.60280","journal-title":"Cureus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.18231\/j.ijirm.2024.001","article-title":"Understanding the complexities of post-tuberculosis lung disease: implications for global health","volume":"9","author":"Yadav S","year":"2024","unstructured":"Yadav S. Understanding the complexities of post-tuberculosis lung disease: implications for global health. IP Indian J Immunol Respir Med. 2024, 9:1-2. 10.18231\/j.ijirm.2024.001","journal-title":"IP Indian J Immunol Respir Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2022.102244","article-title":"Immunologic and imaging signatures in post tuberculosis lung disease","volume":"136","author":"Singh S","year":"2022","unstructured":"Singh S, Allwood BW, Chiyaka TL, et al.. Immunologic and imaging signatures in post tuberculosis lung disease. Tuberculosis (Edinb). 2022, 136:102244. 10.1016\/j.tube.2022.102244","journal-title":"Tuberculosis (Edinb)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1159\/000512531","article-title":"Post-tuberculosis lung disease: clinical review of an under-recognised global challenge","volume":"100","author":"Allwood BW","year":"2021","unstructured":"Allwood BW, Byrne A, Meghji J, Rachow A, van der Zalm MM, Schoch OD. Post-tuberculosis lung disease: clinical review of an under-recognised global challenge. Respiration. 2021, 100:751-63. 10.1159\/000512531","journal-title":"Respiration"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.21.0278","article-title":"The burden and determinants of post-TB lung disease","volume":"25","author":"Mpagama SG","year":"2021","unstructured":"Mpagama SG, Msaji KS, Kaswaga O, et al.. The burden and determinants of post-TB lung disease. Int J Tuberc Lung Dis. 2021, 25:846-53. 10.5588\/ijtld.21.0278","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2023.110817","article-title":"Post-tuberculosis lung disease and inflammatory role players: can we characterise the myriad inflammatory pathways involved to gain a better understanding?","volume":"387","author":"Malefane L","year":"2024","unstructured":"Malefane L, Maarman G. Post-tuberculosis lung disease and inflammatory role players: can we characterise the myriad inflammatory pathways involved to gain a better understanding?. Chem Biol Interact. 2024, 387:110817. 10.1016\/j.cbi.2023.110817","journal-title":"Chem Biol Interact"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0077-2017","article-title":"Tuberculosis and lung damage: from epidemiology to pathophysiology","volume":"27","author":"Ravimohan S","year":"2018","unstructured":"Ravimohan S, Kornfeld H, Weissman D, Bisson GP. Tuberculosis and lung damage: from epidemiology to pathophysiology. Eur Respir Rev. 2018, 27:170077. 10.1183\/16000617.0077-2017","journal-title":"Eur Respir Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.02603","article-title":"The immune mechanisms of lung parenchymal damage in tuberculosis and the role of host-directed therapy","volume":"9","author":"Stek C","year":"2018","unstructured":"Stek C, Allwood B, Walker NF, Wilkinson RJ, Lynen L, Meintjes G. The immune mechanisms of lung parenchymal damage in tuberculosis and the role of host-directed therapy. Front Microbiol. 2018, 9:2603. 10.3389\/fmicb.2018.02603","journal-title":"Front Microbiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/path.2277","article-title":"Cellular and molecular mechanisms of fibrosis","volume":"214","author":"Wynn TA","year":"2008","unstructured":"Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008, 214:199-210. 10.1002\/path.2277","journal-title":"J Pathol"},{"key":"ref12","article-title":"Bronchiectasis","author":"Bird K","year":"2023","unstructured":"Bird K, Memon J. Bronchiectasis. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s43168-022-00112-2","article-title":"The clinical and functional characteristics of bronchiectasis among tuberculosis patients in Upper Egypt: a single-center study","volume":"16","author":"Hashem MK","year":"2022","unstructured":"Hashem MK, Nasim YS, Mohamed-Hussein AA, Shaddad AM. The clinical and functional characteristics of bronchiectasis among tuberculosis patients in Upper Egypt: a single-center study. 2022, 16:15. 10.1186\/s43168-022-00112-2"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21051705","article-title":"Beneficial and detrimental effects of regulatory t cells in neurotropic virus infections","volume":"21","author":"Ciurkiewicz M","year":"2020","unstructured":"Ciurkiewicz M, Herder V, Beineke A. Beneficial and detrimental effects of regulatory t cells in neurotropic virus infections. Int J Mol Sci. 2020, 21:10.3390\/ijms21051705","journal-title":"Int J Mol Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-065990","article-title":"Risk factors and biomarkers for post-tuberculosis lung damage in a Chinese cohort of male smokers and non-smokers: protocol for a prospective observational study","volume":"13","author":"Gai X","year":"2023","unstructured":"Gai X, Cao W, Rao Y, et al.. Risk factors and biomarkers for post-tuberculosis lung damage in a Chinese cohort of male smokers and non-smokers: protocol for a prospective observational study. BMJ Open. 2023, 13:e065990. 10.1136\/bmjopen-2022-065990","journal-title":"BMJ Open"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2018.07.006","article-title":"Post-primary pulmonary TB haemoptysis - when there is more than meets the eye","volume":"25","author":"Seedat UF","year":"2018","unstructured":"Seedat UF, Seedat F. Post-primary pulmonary TB haemoptysis - when there is more than meets the eye. Respir Med Case Rep. 2018, 25:96-9. 10.1016\/j.rmcr.2018.07.006","journal-title":"Respir Med Case Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2014.08.005","article-title":"Nuclear imaging: a powerful novel approach for tuberculosis","volume":"41","author":"Johnson DH","year":"2014","unstructured":"Johnson DH, Via LE, Kim P, Laddy D, Lau CY, Weinstein EA, Jain S. Nuclear imaging: a powerful novel approach for tuberculosis. Nucl Med Biol. 2014, 41:777-84. 10.1016\/j.nucmedbio.2014.08.005","journal-title":"Nucl Med Biol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0221-2022","article-title":"Post-tuberculosis lung impairment: systematic review and meta-analysis of spirometry data from 14\u2009621 people","volume":"32","author":"Ivanova O","year":"2023","unstructured":"Ivanova O, Hoffmann VS, Lange C, Hoelscher M, Rachow A. Post-tuberculosis lung impairment: systematic review and meta-analysis of spirometry data from 14\u2009621 people. Eur Respir Rev. 2023, 32:220221. 10.1183\/16000617.0221-2022","journal-title":"Eur Respir Rev"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.21.0425","article-title":"Clinical standards for the assessment, management and rehabilitation of post-TB lung disease","volume":"25","author":"Migliori GB","year":"2021","unstructured":"Migliori GB, Marx FM, Ambrosino N, et al.. Clinical standards for the assessment, management and rehabilitation of post-TB lung disease. Int J Tuberc Lung Dis. 2021, 25:797-813. 10.5588\/ijtld.21.0425","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.22.0514","article-title":"Post-TB health and wellbeing","volume":"27","author":"Nightingale R","year":"2023","unstructured":"Nightingale R, Carlin F, Meghji J, et al.. Post-TB health and wellbeing. Int J Tuberc Lung Dis. 2023, 27:248-83. 10.5588\/ijtld.22.0514","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2012.02.008","article-title":"Pharmacologic agents for mucus clearance in bronchiectasis","volume":"33","author":"Nair GB","year":"2012","unstructured":"Nair GB, Ilowite JS. Pharmacologic agents for mucus clearance in bronchiectasis. Clin Chest Med. 2012, 33:363-70. 10.1016\/j.ccm.2012.02.008","journal-title":"Clin Chest Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2023.395","article-title":"Long term management of people with post-tuberculosis lung disease","volume":"39","author":"Seo W","year":"2024","unstructured":"Seo W, Kim HW, Kim JS, Min J. Long term management of people with post-tuberculosis lung disease. Korean J Intern Med. 2024, 39:7-24. 10.3904\/kjim.2023.395","journal-title":"Korean J Intern Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2006.08.340","article-title":"Respiratory muscle training in restrictive thoracic disease: a randomized controlled trial","volume":"87","author":"Budweiser S","year":"2006","unstructured":"Budweiser S, Moertl M, J\u00f6rres RA, Windisch W, Heinemann F, Pfeifer M. Respiratory muscle training in restrictive thoracic disease: a randomized controlled trial. Arch Phys Med Rehabil. 2006, 87:1559-65. 10.1016\/j.apmr.2006.08.340","journal-title":"Arch Phys Med Rehabil"},{"key":"ref24","article-title":"Thoracic surgery for haemoptysis in the context of tuberculosis: what is the best management approach?","volume":"6","author":"Halezero\u011flu S","year":"2014","unstructured":"Halezero\u011flu S, Okur E. Thoracic surgery for haemoptysis in the context of tuberculosis: what is the best management approach?. J Thorac Dis. 2014, 6:182-5.","journal-title":"J Thorac Dis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1378\/chest.121.3.789","article-title":"Bronchial artery embolization : experience with 54 patients","volume":"121","author":"Swanson KL","year":"2002","unstructured":"Swanson KL, Johnson CM, Prakash UB, McKusick MA, Andrews JC, Stanson AW. Bronchial artery embolization : experience with 54 patients. Chest. 2002, 121:789-95. 10.1378\/chest.121.3.789","journal-title":"Chest"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-021-01783-1","article-title":"Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis","volume":"21","author":"Finnerty JP","year":"2021","unstructured":"Finnerty JP, Ponnuswamy A, Dutta P, Abdelaziz A, Kamil H. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis. BMC Pulm Med. 2021, 21:411. 10.1186\/s12890-021-01783-1","journal-title":"BMC Pulm Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2020.06.009","article-title":"Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential","volume":"41","author":"Song N","year":"2020","unstructured":"Song N, Scholtemeijer M, Shah K. Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential. Trends Pharmacol Sci. 2020, 41:653-64. 10.1016\/j.tips.2020.06.009","journal-title":"Trends Pharmacol Sci"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2018-000745","article-title":"International research and guidelines on post-tuberculosis chronic lung disorders: a systematic scoping review","volume":"3","author":"van Kampen SC","year":"2018","unstructured":"van Kampen SC, Wanner A, Edwards M, Harries AD, Kirenga BJ, Chakaya J, Jones R. International research and guidelines on post-tuberculosis chronic lung disorders: a systematic scoping review. BMJ Glob Health. 2018, 3:e000745. 10.1136\/bmjgh-2018-000745","journal-title":"BMJ Glob Health"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.2147\/JMDH.S156949","article-title":"Knowledge, beliefs, and perceptions of tuberculosis among community members in Ntcheu district, Malawi","volume":"11","author":"Nyasulu P","year":"2018","unstructured":"Nyasulu P, Sikwese S, Chirwa T, et al.. Knowledge, beliefs, and perceptions of tuberculosis among community members in Ntcheu district, Malawi. J Multidiscip Healthc. 2018, 11:375-89. 10.2147\/JMDH.S156949","journal-title":"J Multidiscip Healthc"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-022-08043-w","article-title":"Integration of systematic screening for tuberculosis in outpatient departments of urban primary healthcare facilities in Zambia: a case study of Kitwe district","volume":"22","author":"Zulu DW","year":"2022","unstructured":"Zulu DW, Silumbwe A, Maritim P, Zulu JM. Integration of systematic screening for tuberculosis in outpatient departments of urban primary healthcare facilities in Zambia: a case study of Kitwe district. BMC Health Serv Res. 2022, 22:732. 10.1186\/s12913-022-08043-w","journal-title":"BMC Health Serv Res"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abj4124","article-title":"Point-of-care diagnostic tests for tuberculosis disease","volume":"14","author":"Hong JM","year":"2022","unstructured":"Hong JM, Lee H, Menon NV, Lim CT, Lee LP, Ong CW. Point-of-care diagnostic tests for tuberculosis disease. Sci Transl Med. 2022, 14:eabj4124. 10.1126\/scitranslmed.abj4124","journal-title":"Sci Transl Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00070-0","article-title":"Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers","volume":"16","author":"Wallis RS","year":"2016","unstructured":"Wallis RS, Maeurer M, Mwaba P, et al.. Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. Lancet Infect Dis. 2016, 16:e34-46. 10.1016\/S1473-3099(16)00070-0","journal-title":"Lancet Infect Dis"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00527","article-title":"Immunometabolic signatures predict risk of progression to active tuberculosis and disease outcome","volume":"10","author":"Duffy FJ","year":"2019","unstructured":"Duffy FJ, Weiner J 3rd, Hansen S, et al.. Immunometabolic signatures predict risk of progression to active tuberculosis and disease outcome. Front Immunol. 2019, 10:527. 10.3389\/fimmu.2019.00527","journal-title":"Front Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/258953-understanding-the-spectrum-and-management-of-post-tuberculosis-lung-disease-a-comprehensive-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:09:56Z","timestamp":1719619796000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/258953-understanding-the-spectrum-and-management-of-post-tuberculosis-lung-disease-a-comprehensive-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":33,"URL":"https:\/\/doi.org\/10.7759\/cureus.63420","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,28]]}}}